FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3195592878> ?p ?o ?g. }

• W3195592878 endingPage "761" @default.
• W3195592878 startingPage "760" @default.
• W3195592878 abstract "We thank Waitzman et al1Waitzman J. Canney M. Hiremath S. Finerenone: fiddling with hyperkalemia?.Am J Kidney Dis. 2021; 78: 760Abstract Full Text Full Text PDF Scopus (2) Google Scholar for their comments. We agree that MRAs raise hyperkalemia risk and should be used cautiously to avoid subsequent higher rates of hyperkalemia.2Juurlink D.N. Mamdani M.M. Lee D.S. et al.Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.N Engl J Med. 2004; 351: 543-551Crossref PubMed Scopus (1371) Google Scholar While there is evidence that nonsteroidal MRAs including finerenone increase potassium to a lesser extent than spironolactone,3Pitt B. Kober L. Ponikowski P. et al.Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial.Eur Heart J. 2013; 34: 2453-2463Crossref PubMed Scopus (272) Google Scholar clinicians will need to exercise caution when using these therapies in patients with CKD. The FIDELIO-DKD protocol offers clinicians guidance on hyperkalemia mitigation and an approach to nonsteroidal MRA initiation.4Bakris G.L. Agarwal R. Anker S.D. et al.Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes.N Engl J Med. 2020; 383: 2219-2229Crossref PubMed Scopus (280) Google Scholar Initiation of finerenone only with serum potassium levels ≤4.8 mmol/L mirrors best clinical practice in that nephrologists would generally not initiate potassium-raising therapies with baseline potassium levels above this range. Importantly, beyond choosing the correct patients for these therapies, hyperkalemia management has evolved compared to the post-RALES era over 20 years ago. Novel potassium binders (patiromer, sodium zirconium cyclosilicate) are evidence-based strategies for controlling hyperkalemia while maximizing renin-angiotensin-aldosterone-system inhibitor therapies.5Agarwal R. Rossignol P. Romero A. et al.Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial.Lancet. 2019; 394: 1540-1550Abstract Full Text Full Text PDF PubMed Scopus (107) Google Scholar Concomitant use of SGLT2 inhibition may also attenuate the hyperkalemia risk in heart failure patients using MRAs.6Kristensen S.L. Docherty K.F. Jhund P.S. et al.Dapagliflozin reduces the risk of hyperkalaemia in patients with heart failure and reduced ejection fraction: a secondary analysis DAPA-HF.Eur Heart J. 2020; 41: 939Google Scholar While we may have an “embarrassment of riches” to manage DKD, uptake of therapies remains unacceptably low. This is despite having data for finerenone in 2 large trials involving >13,000 participants (FIDELIO-DKD and FIGARO)—considerably more data compared to evidence for angiotensin receptor blocker monotherapy for DKD treatment in type 2 diabetes from RENAAL and IDNT. Importantly, clinical uptake of these agents will generate real-world safety and efficacy data for nonsteroidal MRAs in the current era of novel DKD medications and potassium binders. Dr Cherney has received consulting fees or speaking honoraria, or both, from Bristol Myers Squibb, Novo Nordisk, Mitsubishis-Tanabe, MAZE, Janssen, Bayer, Boehringer Ingelheim-Eli Lilly, AstraZeneca, Merck & Co, Inc, Prometic, and Sanofi; and has received operating funds from Janssen, Boehringer Ingelheim-Eli Lilly, Sanofi, AstraZeneca, and Merck & Co, Inc. The remaining authors declare that they have no relevant financial interests. Received August 3, 2021. Accepted August 3, 2021 after editorial review by an Associate Editor and a Deputy Editor. Finerenone: Fiddling With Hyperkalemia?American Journal of Kidney DiseasesVol. 78Issue 5PreviewFinerenone was recently approved by the US Food and Drug Administration for treatment of diabetic kidney disease (DKD). However, the commentary from Sridhar et al1 on the FIDELIO trial2 minimizes hyperkalemia and overstates the superiority of finerenone over other mineralocorticoid receptor antagonists (MRAs). The authors state that few patients discontinued finerenone owing to hyperkalemia (2.3% vs 0.9%). However, the enrollment criteria were crafted to minimize this, requiring a potassium level <4.8 mEq/L during screening and run-in, resulting in almost 60% exclusion. Full-Text PDF" @default.
• W3195592878 created "2021-08-30" @default.
• W3195592878 creator A5010398730 @default.
• W3195592878 creator A5029467844 @default.
• W3195592878 creator A5061406786 @default.
• W3195592878 date "2021-11-01" @default.
• W3195592878 modified "2023-09-25" @default.
• W3195592878 title "In Reply to ‘Finerenone: Fiddling With Hyperkalemia?’" @default.
• W3195592878 cites W2111945961 @default.
• W3195592878 cites W2138612646 @default.
• W3195592878 cites W2972966903 @default.
• W3195592878 cites W3094429645 @default.
• W3195592878 cites W3194565705 @default.
• W3195592878 doi "https://doi.org/10.1053/j.ajkd.2021.08.001" @default.
• W3195592878 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34400242" @default.
• W3195592878 hasPublicationYear "2021" @default.
• W3195592878 type Work @default.
• W3195592878 sameAs 3195592878 @default.
• W3195592878 citedByCount "0" @default.
• W3195592878 crossrefType "journal-article" @default.
• W3195592878 hasAuthorship W3195592878A5010398730 @default.
• W3195592878 hasAuthorship W3195592878A5029467844 @default.
• W3195592878 hasAuthorship W3195592878A5061406786 @default.
• W3195592878 hasBestOaLocation W31955928781 @default.
• W3195592878 hasConcept C126322002 @default.
• W3195592878 hasConcept C168563851 @default.
• W3195592878 hasConcept C177713679 @default.
• W3195592878 hasConcept C2776379505 @default.
• W3195592878 hasConcept C2778198053 @default.
• W3195592878 hasConcept C2778653478 @default.
• W3195592878 hasConcept C2779306644 @default.
• W3195592878 hasConcept C2780072264 @default.
• W3195592878 hasConcept C2780152017 @default.
• W3195592878 hasConcept C2780243291 @default.
• W3195592878 hasConcept C71924100 @default.
• W3195592878 hasConceptScore W3195592878C126322002 @default.
• W3195592878 hasConceptScore W3195592878C168563851 @default.
• W3195592878 hasConceptScore W3195592878C177713679 @default.
• W3195592878 hasConceptScore W3195592878C2776379505 @default.
• W3195592878 hasConceptScore W3195592878C2778198053 @default.
• W3195592878 hasConceptScore W3195592878C2778653478 @default.
• W3195592878 hasConceptScore W3195592878C2779306644 @default.
• W3195592878 hasConceptScore W3195592878C2780072264 @default.
• W3195592878 hasConceptScore W3195592878C2780152017 @default.
• W3195592878 hasConceptScore W3195592878C2780243291 @default.
• W3195592878 hasConceptScore W3195592878C71924100 @default.
• W3195592878 hasIssue "5" @default.
• W3195592878 hasLocation W31955928781 @default.
• W3195592878 hasLocation W31955928782 @default.
• W3195592878 hasOpenAccess W3195592878 @default.
• W3195592878 hasPrimaryLocation W31955928781 @default.
• W3195592878 hasRelatedWork W2042864031 @default.
• W3195592878 hasRelatedWork W2071416829 @default.
• W3195592878 hasRelatedWork W2168712739 @default.
• W3195592878 hasRelatedWork W2981713925 @default.
• W3195592878 hasRelatedWork W3003602067 @default.
• W3195592878 hasRelatedWork W3194565705 @default.
• W3195592878 hasRelatedWork W3201351742 @default.
• W3195592878 hasRelatedWork W3203785131 @default.
• W3195592878 hasRelatedWork W4293920968 @default.
• W3195592878 hasRelatedWork W4297963191 @default.
• W3195592878 hasVolume "78" @default.
• W3195592878 isParatext "false" @default.
• W3195592878 isRetracted "false" @default.
• W3195592878 magId "3195592878" @default.
• W3195592878 workType "article" @default.